Exploring SLC30A6 as a potential prognostic, immunomodulatory, and therapeutic biomarker in various cancers with a focus on pancreatic cancer: a pan-cancer analysis
Abstract Background Our study investigates the multifaceted role of the gene SLC30A6 across 33 distinct cancer types. Understanding the function and impact of SLC30A6 in cancer biology is crucial, as previous studies have hinted at its aberrant expression and potential involvement in tumor progressi...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2024-11-01
|
| Series: | Egyptian Journal of Medical Human Genetics |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s43042-024-00608-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850162471908671488 |
|---|---|
| author | Fatemeh Maghool Parisa Kadkhodaei Elyaderani Samaneh Mohammadzadeh Amir Hosseini Aida Heidari Pouria Samadi |
| author_facet | Fatemeh Maghool Parisa Kadkhodaei Elyaderani Samaneh Mohammadzadeh Amir Hosseini Aida Heidari Pouria Samadi |
| author_sort | Fatemeh Maghool |
| collection | DOAJ |
| description | Abstract Background Our study investigates the multifaceted role of the gene SLC30A6 across 33 distinct cancer types. Understanding the function and impact of SLC30A6 in cancer biology is crucial, as previous studies have hinted at its aberrant expression and potential involvement in tumor progression. This research aims to elucidate the expression patterns, methylation variations, mutational signatures, and survival implications of SLC30A6, along with its engagement with the immune system in various cancers and specially in pancreatic cancer. Methods We conducted a comprehensive analysis of SLC30A6 using data from 33 different cancer types, and all data were analyzed in silico. The study involved examining expression levels, performing correlation analyses with clinical outcomes, assessing methylation variations, and identifying mutational signatures. Functional enrichment analyses were carried out to understand the gene's involvement in biological pathways. Additionally, we evaluated the relationship between SLC30A6 expression and immune cell infiltration levels to uncover its role in the tumor microenvironment. Results SLC30A6 was found to be significantly up-regulated in the majority of the 33 cancer types analyzed. High expression levels of SLC30A6 were consistently correlated with poor survival outcomes, indicating its potential role in cancer prognosis. Functional enrichment analyses revealed that SLC30A6 is involved in key pathways related to tumor progression, including cell proliferation and apoptosis. Moreover, SLC30A6 showed significant associations with diverse immune pathways, suggesting its involvement in immune regulation. Notably, our analysis demonstrated a significant correlation between SLC30A6 expression and the infiltration levels of key immune cells, highlighting its dual immunosuppressive and immunostimulatory roles in a pan-cancer context. Moreover, SLC30A6 is significantly overexpression in pancreatic cancer and have shown different clinical associations as above. Conclusion Our study provides comprehensive insights into the complex interplay between SLC30A6 and cancer development. These findings position SLC30A6 as a promising prognostic biomarker and therapeutic target across diverse cancer types, highlighting its importance in future cancer research and treatment strategies. |
| format | Article |
| id | doaj-art-d6da89bf26b445268253589c0d891084 |
| institution | OA Journals |
| issn | 2090-2441 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | Egyptian Journal of Medical Human Genetics |
| spelling | doaj-art-d6da89bf26b445268253589c0d8910842025-08-20T02:22:33ZengSpringerOpenEgyptian Journal of Medical Human Genetics2090-24412024-11-0125111710.1186/s43042-024-00608-0Exploring SLC30A6 as a potential prognostic, immunomodulatory, and therapeutic biomarker in various cancers with a focus on pancreatic cancer: a pan-cancer analysisFatemeh Maghool0Parisa Kadkhodaei Elyaderani1Samaneh Mohammadzadeh2Amir Hosseini3Aida Heidari4Pouria Samadi5Poursina Hakim Digestive Diseases Research Center, Isfahan University of Medical SciencesPoursina Hakim Digestive Diseases Research Center, Isfahan University of Medical SciencesPoursina Hakim Digestive Diseases Research Center, Isfahan University of Medical SciencesDepartment of Medical Genetics, University of TehranDepartment of Cell and Molecular Biology, Faculty of Biological Science and Technology, University of IsfahanPoursina Hakim Digestive Diseases Research Center, Isfahan University of Medical SciencesAbstract Background Our study investigates the multifaceted role of the gene SLC30A6 across 33 distinct cancer types. Understanding the function and impact of SLC30A6 in cancer biology is crucial, as previous studies have hinted at its aberrant expression and potential involvement in tumor progression. This research aims to elucidate the expression patterns, methylation variations, mutational signatures, and survival implications of SLC30A6, along with its engagement with the immune system in various cancers and specially in pancreatic cancer. Methods We conducted a comprehensive analysis of SLC30A6 using data from 33 different cancer types, and all data were analyzed in silico. The study involved examining expression levels, performing correlation analyses with clinical outcomes, assessing methylation variations, and identifying mutational signatures. Functional enrichment analyses were carried out to understand the gene's involvement in biological pathways. Additionally, we evaluated the relationship between SLC30A6 expression and immune cell infiltration levels to uncover its role in the tumor microenvironment. Results SLC30A6 was found to be significantly up-regulated in the majority of the 33 cancer types analyzed. High expression levels of SLC30A6 were consistently correlated with poor survival outcomes, indicating its potential role in cancer prognosis. Functional enrichment analyses revealed that SLC30A6 is involved in key pathways related to tumor progression, including cell proliferation and apoptosis. Moreover, SLC30A6 showed significant associations with diverse immune pathways, suggesting its involvement in immune regulation. Notably, our analysis demonstrated a significant correlation between SLC30A6 expression and the infiltration levels of key immune cells, highlighting its dual immunosuppressive and immunostimulatory roles in a pan-cancer context. Moreover, SLC30A6 is significantly overexpression in pancreatic cancer and have shown different clinical associations as above. Conclusion Our study provides comprehensive insights into the complex interplay between SLC30A6 and cancer development. These findings position SLC30A6 as a promising prognostic biomarker and therapeutic target across diverse cancer types, highlighting its importance in future cancer research and treatment strategies.https://doi.org/10.1186/s43042-024-00608-0SLC30A6Pan-cancerPrognostic biomarkerImmunotherapyMethylation |
| spellingShingle | Fatemeh Maghool Parisa Kadkhodaei Elyaderani Samaneh Mohammadzadeh Amir Hosseini Aida Heidari Pouria Samadi Exploring SLC30A6 as a potential prognostic, immunomodulatory, and therapeutic biomarker in various cancers with a focus on pancreatic cancer: a pan-cancer analysis Egyptian Journal of Medical Human Genetics SLC30A6 Pan-cancer Prognostic biomarker Immunotherapy Methylation |
| title | Exploring SLC30A6 as a potential prognostic, immunomodulatory, and therapeutic biomarker in various cancers with a focus on pancreatic cancer: a pan-cancer analysis |
| title_full | Exploring SLC30A6 as a potential prognostic, immunomodulatory, and therapeutic biomarker in various cancers with a focus on pancreatic cancer: a pan-cancer analysis |
| title_fullStr | Exploring SLC30A6 as a potential prognostic, immunomodulatory, and therapeutic biomarker in various cancers with a focus on pancreatic cancer: a pan-cancer analysis |
| title_full_unstemmed | Exploring SLC30A6 as a potential prognostic, immunomodulatory, and therapeutic biomarker in various cancers with a focus on pancreatic cancer: a pan-cancer analysis |
| title_short | Exploring SLC30A6 as a potential prognostic, immunomodulatory, and therapeutic biomarker in various cancers with a focus on pancreatic cancer: a pan-cancer analysis |
| title_sort | exploring slc30a6 as a potential prognostic immunomodulatory and therapeutic biomarker in various cancers with a focus on pancreatic cancer a pan cancer analysis |
| topic | SLC30A6 Pan-cancer Prognostic biomarker Immunotherapy Methylation |
| url | https://doi.org/10.1186/s43042-024-00608-0 |
| work_keys_str_mv | AT fatemehmaghool exploringslc30a6asapotentialprognosticimmunomodulatoryandtherapeuticbiomarkerinvariouscancerswithafocusonpancreaticcancerapancanceranalysis AT parisakadkhodaeielyaderani exploringslc30a6asapotentialprognosticimmunomodulatoryandtherapeuticbiomarkerinvariouscancerswithafocusonpancreaticcancerapancanceranalysis AT samanehmohammadzadeh exploringslc30a6asapotentialprognosticimmunomodulatoryandtherapeuticbiomarkerinvariouscancerswithafocusonpancreaticcancerapancanceranalysis AT amirhosseini exploringslc30a6asapotentialprognosticimmunomodulatoryandtherapeuticbiomarkerinvariouscancerswithafocusonpancreaticcancerapancanceranalysis AT aidaheidari exploringslc30a6asapotentialprognosticimmunomodulatoryandtherapeuticbiomarkerinvariouscancerswithafocusonpancreaticcancerapancanceranalysis AT pouriasamadi exploringslc30a6asapotentialprognosticimmunomodulatoryandtherapeuticbiomarkerinvariouscancerswithafocusonpancreaticcancerapancanceranalysis |